NanoViricides, Inc. (NYSEAmerican:NNVC) said its antiviral candidate NV-387 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of measles, marking a regulatory milestone as the company advances its clinical-stage pipeline.
The designation, awarded by the FDA’s Office of Orphan Products Development, provides incentives including tax credits for qualifying clinical trials, potential exemption from certain regulatory fees, and up to seven years of market exclusivity upon approval.
NV-387 is a broad-spectrum antiviral developed using the company’s nanomedicine platform. NanoViricides indicated the candidate has demonstrated antiviral activity in preclinical studies, including animal models of measles infection, though the therapy remains in the clinical development stage and has not yet received regulatory approval.
The announcement comes as measles cases have risen globally and in the United States, according to public health data. While measles remains relatively rare in the U.S. compared with global incidence levels, periodic outbreaks have been reported in recent years, particularly in under-vaccinated populations.
Orphan Drug Designation is typically granted to therapies targeting conditions affecting fewer than 200,000 people annually in the United States. The status is designed to encourage development of treatments for rare diseases where commercial incentives may otherwise be limited.
In addition to the orphan designation, the company said it has applied for Rare Pediatric Disease status for NV-387. If granted, this could make the program eligible for a Priority Review Voucher, which can accelerate FDA review timelines and may be transferable.
NanoViricides has positioned NV-387 as its lead drug candidate, with potential applications across multiple viral infections, including respiratory viruses. The company is working toward advancing the therapy into later-stage clinical trials, although timelines remain subject to regulatory and development progress.
Currently, there are no approved antiviral treatments specifically for measles, with prevention primarily reliant on vaccination programs. Public health responses to outbreaks typically involve isolation and contact tracing to limit transmission.
As a clinical-stage biotechnology company, NanoViricides continues to face typical development risks, including the need to demonstrate safety and efficacy in human trials and to secure regulatory approvals before commercialization.
Investors will likely monitor further updates on clinical progress, regulatory designations, and potential partnerships as key indicators of the program’s trajectory.
